Reading a Peptide HPLC Trace — A 5-Minute Field Guide for Bench Scientists. Read our briefing →
Reading a peptide HPLC trace — a field guide. Read →
On reading HPLC traces. Read →
GIP / GLP-1 dual receptor agonist · 39-mer metabolic research peptide
Overview
Tirzepatide is a 39-amino-acid synthetic peptide that acts as a balanced dual agonist of the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. A C20 fatty-diacid moiety on a lysine side chain drives reversible albumin binding and the extended pharmacokinetic profile that distinguishes it from the GLP-1 mono-agonist class. In the published metabolic-research literature it is a reference dual-incretin agonist; it is also the active ingredient of approved finished drugs under separate brand names, but the material supplied here is a research reagent only. Lyochem characterizes each Tirzepatide lot as an analytical reference standard rather than a bulk commodity. Every vial ships with its own data packet: RP-HPLC purity (gradient method, UV 214 nm), ESI-MS identity within 0.5 Da of the theoretical 4813.45 g/mol, sequence confirmation by LC-MS/MS, counter-ion content, peptide content (% net peptide), and water content by Karl Fischer. Sequence verification by tandem MS is recommended at first-time qualification of any new source because the closely-eluting deletion sequences from a 39-mer SPPS run are not resolvable by mass alone. Bacterial endotoxin (LAL) is available on request for in vivo metabolic-model work. Fills run mg-scale for reproducible aliquoting across a study series; this is reference-grade research material, distinct from compounding-scale API supply.
Who buys this, and why
GLP-1 and metabolic-peptide buyers run incretin-pathway, body-composition, glucose-regulation, and energy-expenditure studies. Because the receptor pharmacology is sequence-sensitive, qualifying a new source means confirming identity within 0.5 Da of theoretical by ESI-MS, sequence verification by tandem MS on the first lot, and lot-to-lot consistency for reproducible metabolic research. Lyochem supplies this class reference-grade and mg-scale — distinct from compounding-grade (g/kg) API supply.
Primary buyer fit: academic laboratories at universities and government research institutes and biotech and pharmaceutical R&D groups running preclinical discovery.
Specifications
Documentation available on request
Regulatory note
Sold for Research Use Only under the receiving laboratory's institutional and jurisdictional regulations. Not a finished dosage form and not labelled for human administration. Tirzepatide is the active ingredient of approved finished drugs under separate brand names, but the bulk active supplied here is a research reagent; buyers are responsible for institutional biosafety review and verifying import eligibility in the destination market.
Frequently asked questions
Tirzepatide CAS is 2023788-19-2; molecular formula C225H348N48O68; average molecular weight 4813.45 g/mol. It is a 39-amino-acid synthetic peptide carrying a C20 fatty-diacid albumin-binding moiety on a lysine side chain. Every Lyochem lot confirms identity by ESI-MS within 0.5 Da of the theoretical mass, with the full reference set (CAS, formula, MW, sequence-verification result) reproduced on the batch COA so the value can be cited directly in a methods section.
Mass spec alone confirms the intact mass but cannot separate a correctly-synthesized 39-mer from closely-related deletion or aspartimide by-products that co-elute on RP-HPLC. Lyochem confirms identity with a combination of RP-HPLC purity (gradient method, 214 nm), ESI-MS within 0.5 Da of 4813.45 g/mol, and sequence verification by LC-MS/MS (b/y-ion ladder). For a lab qualifying a new source, request the tandem-MS sequence data on the first lot; that is the test that demonstrates the supplied sequence matches the labelled sequence rather than only matching the labelled mass.
Both are once-weekly fatty-acid-conjugated incretin-pathway peptides, but the receptor profile differs: Semaglutide is a selective GLP-1 mono-agonist (31 amino acids, C18 fatty-diacid), while Tirzepatide is a balanced GIP / GLP-1 dual agonist (39 amino acids, C20 fatty-diacid). In published metabolic-research readouts the dual-incretin mechanism produces larger effects on glucose handling and body composition than the GLP-1 mono-agonist class at comparable exposures, which is the reason it is a frequent comparator in incretin-pharmacology studies.
Lyochem supplies Tirzepatide as a reference-grade research reagent, mg-scale, characterized lot-by-lot for reproducible bench and in vivo metabolic research and labelled strictly Research Use Only. That is a different scope from compounding-grade or kg-scale API supply intended for finished-dose preparation. Buyers whose workflow is pharmacy-compounding rather than research should source through a supplier scoped to that use; Lyochem's lots are scoped to the research-documentation chain (HPLC trace, mass spec, sequence verification, stability) that a lab needs to cite in a paper.
Related peptides
GLP-1 receptor agonist · 31-mer metabolic research peptide
GIP / GLP-1 / glucagon tri-agonist · 39-mer metabolic research peptide
Modified HGH fragment 176–191 (anti-obesity drug candidate)